



## **Aerpio Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference**

March 20, 2018

CINCINNATI--(BUSINESS WIRE)--Mar. 20, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 17<sup>th</sup> Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 3:00 p.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.

The presentation will be webcast live and may be accessed by visiting Aerpio's website at <http://ir.aerpio.com/>.

### **About Aerpio Pharmaceuticals**

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company's lead compound, AKB-9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy. For more information please visit [www.aerpio.com](http://www.aerpio.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180320005716/en/>

Source: Aerpio Pharmaceuticals, Inc.

### **Investor & Media:**

#### **Aerpio Pharmaceuticals, Inc.**

Michael Rogers, 513-985-1958

Chief Financial Officer

or

#### **Burns McClellan, on behalf of Aerpio Pharmaceuticals, Inc.**

Media:

Justin Jackson

[jjackson@burnsmc.com](mailto:jjackson@burnsmc.com)

or

Investors:

Ami Bavishi

[abavishi@burnsmc.com](mailto:abavishi@burnsmc.com)